Phase II study shows improved progression-free and overall survival with pumitamig in EGFR-mutated NSCLC, suggesting potential benefits for patients post-TKI treatment.
Pumitamig (BNT327/BMS986545) is an investigational bispecific antibody designed to target both PD-L1 and VEGF-A in the tumor and tumor microenvironment that has shown encouraging antitumor activity in combination with chemo in pts with previously treated EGFR-mutated NSCLC. Here, we present PFS and OS data from an ongoing single-arm phase II study of pumitamig + chemo in pts with EGFR-mutated advanced NSCLC who progressed on or after standard EGFR TKI treatment.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: